Results 21 to 30 of about 70,211 (203)

Ras/Raf-1/MAPK pathway mediates response to tamoxifen but not chemotherapy in breast cancer patients [PDF]

, 2009
<b>Purpose</b>: The expression and activation of the Ras/Raf-1/mitogen-activated protein kinase (MAPK) pathway plays an important role in the development and progression of cancer, and may influence response to treatments such as tamoxifen ...
Bartlett, J.M.S., Cameron, D., Cooke, T.G., Edwards, J., Kirkegaard, T., McGlynn, L.M., Tovey, S., Twelves, C.   +7 more
core   +1 more source

miR-449a Suppresses Tamoxifen Resistance in Human Breast Cancer Cells by Targeting ADAM22

Cellular Physiology and Biochemistry, 2018
Background/Aims: Most of estrogen receptor positive breast cancer patients respond well initially to endocrine therapies, but often develop resistance during treatment with selective estrogen receptor modulators (SERMs) such as tamoxifen.
Jun Li, Mingjie Lu, Jiao Jin, Xiyi Lu, Tongpeng Xu, Shidai Jin   +5 more
doaj   +1 more source

Upregulation of PI3K/AKT/PTEN pathway is correlated with glucose and glutamine metabolic dysfunction during tamoxifen resistance development in MCF-7 cells

Scientific Reports, 2020
Tamoxifen resistance is emerging as a big challenge in endocrine therapy of luminal A breast cancer patients. In this study, we aimed to determine the molecular changes of PI3K/AKT/PTEN signaling pathway during tamoxifen-resistance development using ...
Lama Hamadneh, Rama Abuarqoub, Ala Alhusban, Mohamad Bahader   +3 more
doaj   +1 more source

Tamoxifen resistance-related ceRNA network for breast cancer. [PDF]

Front Cell Dev Biol, 2022
Background: Tamoxifen (TMX) is one of the most widely used drugs to treat breast cancer (BC). However, acquired drug resistance is still a major obstacle to its application, rendering it crucial to explore the mechanisms of TMX resistance in BC. This aims of this study were to identify the mechanisms of TMX resistance and construct ceRNA regulatory ...
Qiao Z, Xing Y, Zhang Q, Tang Y, Feng R, Pang W.   +5 more
europepmc   +4 more sources

Fee Arrangements and Fee Shifting: Lessons From the Experience in Ontario [PDF]

, 1984
About one-third of oestrogen receptor alpha-positive breast cancer patients treated with tamoxifen relapse. Here we identify the nuclear receptor retinoic acid receptor alpha as a marker of tamoxifen resistance. Using quantitative mass spectrometry-based
Forshed, Jenny, Helou, Khalil, Hjerpe, Anders, Hultin-Rosenberg, Lina, Johansson, Henrik J., Kanter, Lena, Kovacs, Aniko, Krawiec, Kamilla, Lehtio, Janne, Linderholm, Barbro K., Lundgren, Bo, Martens, Ulf, Mathe, Gyongyver, Mundt, Filip, Panizza, Elena, Sanchez, Betzabe C., Stål, Olle, Yakhini, Zohar   +17 more
core   +3 more sources

Elevated Expression of MAPK Phosphatase 3 in Breast Tumors—A Mechanism of Tamoxifen Resistance [PDF]

, 2006
Antiestrogen resistance is a major clinical problem in the treatment of breast cancer. Altered growth factor signaling with estrogen receptor (ER) α has been shown to be associated with the development of resistance.
Cui, Yukun, Fuqua, Suzanne A. W., Furukawa, Toru, Hilsenbeck, Susan G., Horii, Akira, Nicholson, Robert I., Parra, Irma, Tsimelzon, Anna, Zhang, Mao, Zhang, Zhong-Yin   +9 more
core   +1 more source

Neoadjuvant endocrine therapy for luminal breast cancer treatment: a first-choice alternative in times of crisis such as the COVID-19 pandemic [PDF]

, 2020
The epidemiological emergency caused by CoV-2 (COVID-19) has changed priorities in breast cancer management. In those places where the pandemic has had the greatest effect, it is of paramount importance for most patients to be at home, reducing or ...
Martí, Covadonga, Sánchez-Méndez, José I.   +1 more
core   +1 more source

The lncRNA landscape of breast cancer reveals a role for DSCAM-AS1 in breast cancer progression. [PDF]

, 2016
Molecular classification of cancers into subtypes has resulted in an advance in our understanding of tumour biology and treatment response across multiple tumour types. However, to date, cancer profiling has largely focused on protein-coding genes, which
Backofen, Rolf, Cao, Xuhong, Chinnaiyan, Arul M, Collins, Colin, Feng, Felix Y, Gawronski, Alexander, Han, Sumin, Hayes, Daniel F, Hosono, Yasuyuki, Iyer, Matthew K, Kregel, Steven, Ma, Teng, Malik, Rohit, Niknafs, Yashar S, Pierce, Lori J, Pitchiaya, Sethuramasundaram, Poliakov, Anton, Prensner, John R, Rae, James M, Sahinalp, Cenk S, Siebenaler, Ronald F, Singhal, Udit, Speers, Corey, Uhl, Michael, Wilder-Romans, Kari, Xiao, Lanbo, Zhang, Chao, Zhao, Shuang G   +27 more
core   +1 more source

IGF1R signaling drives antiestrogen resistance through PAK2/PIX activation in luminal breast cancer [PDF]

, 2018
Antiestrogen resistance in estrogen receptor positive (ER+) breast cancer is associated with increased expression and activity of insulin-like growth factor 1 receptor (IGF1R).
Berns, P.M.J.J. (Els), Danen, E.H.J. (Erik H. J.), de Graauw, M. (Marjo), Geiger, T. (Tamar), He, J. (Jichao), Helmijr, J. (Jean), Jansen, M.P.H.M. (Maurice), Look, M.P. (Maxime), Martens, J.W.M. (John), Meerman, J.H.N. (John H.), Moerkens, M. (Marja), Pont, C., Siddappa, R. (Ram), Timmermans, M.M. (Mieke M.), Van de Water, B. (Bob), van Deurzen, C.H.M. (Caroline H. M.), Wester, L. (Lynn), Zhang, Y. (Yinghui)   +17 more
core   +5 more sources

Functional network analysis of p85 and PI3K as potential gene targets and mechanism of oleanolic acid in overcoming breast cancer resistance to tamoxifen

Journal of Genetic Engineering and Biotechnology, 2022
Background Tamoxifen resistance in estrogen receptor positive (ER+) breast cancer therapy increases, which is the leading cause of cancer treatment failure, as it can impair patients’ prognoses, cause cancer recurrence, metastasis, and death. Combination
Wilfan Ibadurrahman, Naufa Hanif, Adam Hermawan   +2 more
doaj   +1 more source